MCID: RYN005
MIFTS: 51

Raynaud Phenomenon

Categories: Blood diseases, Cardiovascular diseases, Ear diseases, Rare diseases, Smell/Taste diseases

Aliases & Classifications for Raynaud Phenomenon

MalaCards integrated aliases for Raynaud Phenomenon:

Name: Raynaud Phenomenon 25 73
Raynaud Disease 25 73
Raynaud's 25 63
Secondary Raynaud's Phenomenon 73
Raynaud's Phenomenon 25
Raynauds Phenomenon 55
Raynaud's Syndrome 25
Raynaud's Disease 25
Raynauds Syndrome 55
Raynaud Syndrome 37

Classifications:



External Ids:

KEGG 37 H01620
ICD10 33 I73.0

Summaries for Raynaud Phenomenon

PubMed Health : 63 About raynaud's: Raynaud's is a rare disorder that affects the arteries. Arteries are blood vessels that carry blood from your heart to different parts of your body.Raynaud's sometimes is called a disease, syndrome, or phenomenon. The disorder is marked by brief episodes of vasospasm (VA-so-spazm), which is a narrowing of the blood vessels.Vasospasm of the arteries reduces blood flow to the fingers and toes. In people who have Raynaud's, the disorder usually affects the fingers. In about 40 percent of people who have Raynaud's, it affects the toes. Rarely, the disorder affects the nose, ears, nipples, and lips.

MalaCards based summary : Raynaud Phenomenon, also known as raynaud disease, is related to scleroderma, familial progressive and raynaud disease, and has symptoms including nausea and vomiting, constipation and fever. An important gene associated with Raynaud Phenomenon is EDN1 (Endothelin 1), and among its related pathways/superpathways are Response to elevated platelet cytosolic Ca2+ and Vascular smooth muscle contraction. The drugs Cilostazol and Acetylcholine have been mentioned in the context of this disorder. Affiliated tissues include heart, skin and endothelial.

Genetics Home Reference : 25 Raynaud phenomenon is a condition in which the body's normal response to cold or emotional stress is exaggerated, resulting in abnormal spasms (vasospasms) in small blood vessels called arterioles. The disorder mainly affects the fingers but can also involve the ears, nose, nipples, knees, or toes. The vasospasms reduce blood circulation, leading to discomfort and skin color changes.

Wikipedia : 76 Raynaud syndrome, also known as Raynaud''s phenomenon, is a medical condition in which spasm of arteries... more...

Related Diseases for Raynaud Phenomenon

Diseases related to Raynaud Phenomenon via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 104)
# Related Disease Score Top Affiliating Genes
1 scleroderma, familial progressive 32.5 APOH EDN1
2 raynaud disease 32.3 EDN1 VWF
3 purpura 29.8 APOH THBD VWF
4 pulmonary hypertension 29.7 EDN1 PDE5A THBD VWF
5 pulmonary hypertension, primary, 1 29.7 EDN1 PDE5A THBD
6 antiphospholipid syndrome 29.6 APOH THBD VWF
7 vasculitis 29.6 APOH THBD VWF
8 buerger disease 29.5 APOH HTR2A
9 vascular disease 29.3 APOH EDN1 THBD VWF
10 crest syndrome 11.8
11 angiopathy, hereditary, with nephropathy, aneurysms, and muscle cramps 11.2
12 reynolds syndrome 11.2
13 moyamoya disease 6 with or without achalasia 11.2
14 antisynthetase syndrome 11.2
15 undifferentiated connective tissue disease 11.2
16 unilateral absence of a pulmonary artery 10.2 THBD VWF
17 eclampsia 10.2 EDN1 THBD
18 hepatic vascular disease 10.1 EDN1 VWF
19 grange syndrome 10.1 THBD VWF
20 spotted fever 10.1 THBD VWF
21 angina pectoris 10.1 EDN1 VWF
22 coronary artery vasospasm 10.1 EDN1 HTR2A
23 hepatopulmonary syndrome 10.1 EDN1 VWF
24 limb ischemia 10.1 EDN1 VWF
25 blood coagulation disease 10.1 THBD VWF
26 aortic coarctation 10.1 AGTR1 EDN1
27 apnea, obstructive sleep 10.1 EDN1 HTR2A
28 malignant hypertension 10.1 AGTR1 EDN1
29 myocardial stunning 10.1 AGTR1 EDN1
30 renal hypertension 10.1 AGTR1 EDN1
31 takayasu arteritis 10.1 THBD VWF
32 renovascular hypertension 10.1 AGTR1 EDN1
33 hemolytic uremic syndrome, atypical 1 10.1 THBD VWF
34 connective tissue disease 10.1
35 sexual disorder 10.1 EDN1 PDE5A
36 acute mountain sickness 10.1 AGTR1 EDN1
37 peripheral vascular disease 10.1 THBD VWF
38 eisenmenger syndrome 10.0 EDN1 THBD VWF
39 persistent fetal circulation syndrome 10.0 EDN1 PDE5A
40 diabetic angiopathy 10.0 EDN1 THBD VWF
41 oligohydramnios 10.0 AGTR1 EDN1
42 psychosexual disorder 10.0 HTR2A PDE5A
43 sleep apnea 10.0 EDN1 HTR2A
44 impotence 10.0 EDN1 PDE5A
45 intracranial thrombosis 10.0 APOH VWF
46 portal hypertension 10.0 AGTR1 EDN1 VWF
47 arteries, anomalies of 10.0 AGTR1 EDN1 VWF
48 acute myocardial infarction 10.0 AGTR1 EDN1 VWF
49 coronary heart disease 1 10.0 AGTR1 EDN1 VWF
50 systemic lupus erythematosus 10.0

Comorbidity relations with Raynaud Phenomenon via Phenotypic Disease Network (PDN):


Deficiency Anemia Esophagitis
Hypertension, Essential Hypothyroidism
Ischemic Heart Disease Peripheral Vascular Disease
Systemic Lupus Erythematosus Systemic Scleroderma

Graphical network of the top 20 diseases related to Raynaud Phenomenon:



Diseases related to Raynaud Phenomenon

Symptoms & Phenotypes for Raynaud Phenomenon

UMLS symptoms related to Raynaud Phenomenon:


nausea and vomiting, constipation, fever, fatigue, angina pectoris, abdominal pain, edema, pruritus, pain, chest pain, diarrhea, headache, syncope, chronic pain, sciatica, pelvic pain, coughing, cold intolerance, icterus, vertigo/dizziness, dyspepsia, heartburn, gastrointestinal gas, symptoms, halitosis, joint or joint related complaint

Drugs & Therapeutics for Raynaud Phenomenon

PubMedHealth treatment related to Raynaud Phenomenon: 63

Primary Raynaud's (Raynaud's disease) and secondary Raynaud's (Raynaud's phenomenon) have no cure. However, treatments can reduce the number and severity of Raynaud's attacks. Treatments include lifestyle changes, medicines, and, rarely, surgery.Most people who have primary Raynaud's can manage the condition with lifestyle changes. People who have secondary Raynaud's may need medicines in addition to lifestyle changes. Rarely, they may need surgery or shots.If you have Raynaud's and develop sores on your fingers, toes, or other parts of your body, see your doctor right away. Timely treatment can help prevent permanent damage to these areas.

Drugs for Raynaud Phenomenon (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 153)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
2
Acetylcholine Approved Phase 4,Phase 3,Phase 2,Not Applicable 51-84-3 187
3
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
4 Platelet Aggregation Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
5 Vasodilator Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
6 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
7 Protective Agents Phase 4,Early Phase 1
8 Phosphodiesterase 3 Inhibitors Phase 4
9 Respiratory System Agents Phase 4
10 Fibrinolytic Agents Phase 4
11 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
12 Anti-Asthmatic Agents Phase 4
13 Autonomic Agents Phase 4,Early Phase 1
14 Bronchodilator Agents Phase 4
15 Neuroprotective Agents Phase 4,Early Phase 1
16 Phosphodiesterase Inhibitors Phase 4,Phase 2,Phase 3,Not Applicable,Early Phase 1
17 Acetylcholine Release Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
18 abobotulinumtoxinA Phase 4,Phase 3,Phase 2,Not Applicable
19 onabotulinumtoxinA Phase 4,Phase 3,Phase 2,Not Applicable
20 Cholinergic Agents Phase 4,Phase 3,Phase 2,Not Applicable
21 Botulinum Toxins Phase 4,Phase 3,Phase 2,Not Applicable
22 Botulinum Toxins, Type A Phase 4,Phase 3,Phase 2,Not Applicable
23 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Not Applicable
24 Neuromuscular Agents Phase 4,Phase 3,Phase 2,Not Applicable
25 Analgesics Phase 4,Phase 3
26 Anti-Inflammatory Agents Phase 4,Early Phase 1
27 Analgesics, Non-Narcotic Phase 4,Phase 3
28 Antirheumatic Agents Phase 4,Phase 2
29 Cyclooxygenase Inhibitors Phase 4
30 Anti-Inflammatory Agents, Non-Steroidal Phase 4
31 Antipyretics Phase 4
32
Nitroglycerin Approved, Investigational Phase 3,Phase 2,Phase 1 55-63-0 4510
33
Nitrous oxide Approved, Vet_approved Phase 3,Not Applicable 10024-97-2 948
34
Amlodipine Approved Phase 2, Phase 3 88150-42-9 2162
35
Tadalafil Approved, Investigational Phase 3,Phase 2,Not Applicable 171596-29-5 110635
36
Iloprost Approved, Investigational Phase 3,Phase 2,Not Applicable 78919-13-8 6443959
37
Nifedipine Approved Phase 3,Early Phase 1,Not Applicable 21829-25-4 4485
38
Lidocaine Approved, Vet_approved Phase 3 137-58-6 3676
39
Prilocaine Approved Phase 3 721-50-6 4906
40
Citric Acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3,Phase 3,Early Phase 1 77-92-9 311
41
St. John's Wort Approved, Investigational, Nutraceutical Phase 3 84082-80-4
42
Udenafil Investigational Phase 2, Phase 3 268203-93-6 6918523
43 Fasudil Investigational Phase 3 103745-39-7
44 Antihypertensive Agents Phase 2, Phase 3,Phase 1,Not Applicable,Early Phase 1
45 Sildenafil Citrate Phase 2, Phase 3,Phase 3,Early Phase 1,Not Applicable 171599-83-0
46 Citrate Phase 2, Phase 3,Phase 3,Early Phase 1
47 Phosphodiesterase 5 Inhibitors Phase 2, Phase 3,Phase 3,Not Applicable,Early Phase 1
48 Calcium, Dietary Phase 2, Phase 3,Phase 3,Early Phase 1,Not Applicable
49 calcium channel blockers Phase 2, Phase 3,Phase 3,Early Phase 1
50 Vardenafil Dihydrochloride Phase 2, Phase 3

Interventional clinical trials:

(show top 50) (show all 87)
# Name Status NCT ID Phase Drugs
1 Safety and Efficacy of Pletal(Cilostazol) for the Treatment of Juvenile Primary and Secondary Raynaud’s Phenomenon Completed NCT00048763 Phase 4 Pletal
2 Safety and Efficacy of Pletal (Cilostazol) for the Treatment of Juvenile Primary and Secondary Raynaud’s Phenomenon Completed NCT00048776 Phase 4 Pletal
3 The Effect of Abobotulinum Toxin A on the Symptoms of Raynaud's Phenomenon Recruiting NCT03639766 Phase 4 AbobotulinumtoxinA
4 Evaluation of Effectiveness of Acetylsalicylic Acid on Markers of Vascular Dysfunction in Scleroderma Patients Enrolling by invitation NCT03558854 Phase 4 Acetylsalicylic acid;Placebo oral capsule
5 Study of a Topical Formulation for the Treatment and Prevention of Raynaud's Phenomenon Symptoms Unknown status NCT00934427 Phase 3 0.9% nitroglycerin in TAM cream;vehicle cream
6 A Study of a Topical Form of Nitroglycerin and Placebo in the Treatment and Prevention of Raynaud's Phenomenon Unknown status NCT00577304 Phase 3 Nitroglycerin;Topical AmphiMatrix
7 "As Required" Oral Sildenafil in Raynaud's Phenomenon Completed NCT02050360 Phase 2, Phase 3 Sildenafil 40 mg;Sildenafil 80 mg;Placebo
8 Efficacy Study of PDE-5 Inhibitor and Calcium Channel Inhibitor for the Treatment of Secondary Raynaud Phenomenon Completed NCT01280266 Phase 2, Phase 3 Udenafil or Amlodipine
9 A Randomized Control Trial to Assess the Efficacy of Tadalafil in Raynaud's Phenomenon in Scleroderma Completed NCT01117298 Phase 3 Tadalafil;Placebo
10 Effects of Vardenafil on Clinical Symptoms and Peripheral Blood Flow in Patients With Raynaud's Syndrome Completed NCT01291199 Phase 2, Phase 3 vardenafil;Placebo
11 A Rho-kinase Inhibitor (Fasudil) in the Treatment of Raynaud's Phenomenon Completed NCT00498615 Phase 3 Fasudil
12 St. John's Wort in the Treatment of Raynaud's Phenomenon Completed NCT00351117 Phase 3 St. John's Wort;Lactose
13 Phase III Study of Topical Gel for Treatment and Prevention of Raynaud's Phenomenon Completed NCT00266669 Phase 3 Topical organogel with nitroglycerin
14 Efficacy of Botulinum Toxin In Scleroderma-Associated Raynaud's Syndrome Completed NCT02165111 Phase 3 Onabotulinumtoxin A;sterile saline solution
15 Randomised Control Trial to Assess the Efficacy of Tadalafil in Raynaud's Phenomenon in Scleroderma Completed NCT00626665 Phase 3 Tadalafil
16 Phase III Study of a Topical Gel Formulation for Treatment and Prevention of Raynaud's Phenomenon Completed NCT00419419 Phase 3 Topical AmphiMatrix with nitroglycerin (MQX-503)
17 Phase III Randomized, Double-Blind, Placebo-Controlled Study of Oral Iloprost for Raynaud's Phenomenon Secondary to Systemic Sclerosis Completed NCT00004786 Phase 3 iloprost
18 Lab Study of MQX-503 in Treatment of Raynaud's Completed NCT00253331 Phase 2, Phase 3 topical organogel with nitroglycerin
19 Effect of Sildenafil on the Microcirculatory Blood Flow and Endothelial Progenitor Cells in Systemic Sclerosis Completed NCT01347008 Phase 3 Sildenafil citrate;Placebo (Sugar pill)
20 A Trial of Tadalafil in Interstitial Lung Disease of Scleroderma Completed NCT01553981 Phase 3 Tadalafil;Placebo
21 Raynaud's Treatment Study (RTS) Completed NCT00000530 Phase 3 nifedipine
22 Sildenafil Effect on Digital Ulcer Healing in sClerodErma SEDUCE STUDY Completed NCT01295736 Phase 3 Sildenafil;placebo
23 A Study of RoActemra/Actemra (Tocilizumab) Versus Placebo in Patients With Systemic Sclerosis Completed NCT01532869 Phase 3 Placebo;tocilizumab [RoActemra/Actemra];tocilizumab [RoActemra/Actemra]
24 Efficacy of Botulinum Toxin A in Adult Subjects With Raynaud Phenomenon Secondary to Systemic Sclerosis Recruiting NCT03717961 Phase 3 BOTOX® solution;Placebo group
25 Safety and Efficacy Study of Gene Therapy Drug (Neovasculgen) to Treat Secondary Raynaud's Phenomenon Unknown status NCT02356809 Phase 1, Phase 2 Neovasculgen
26 CSL Behring Sclero XIII Unknown status NCT02551042 Phase 2 Fibrogammin®P, coagulation factor XIII concentrate (Human);0.9% sodium chloride
27 Subcutaneous Injection of Autologous Adipose Tissue-derived Stromal Vascular Fraction Into the Fingers of Patients With Systemic Sclerosis Unknown status NCT02558543 Phase 2 Stromal Vascular fraction;Ringer lactate
28 Effects of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis Completed NCT02260557 Phase 2 Selexipag;Placebo
29 Study of Acute Peripheral Vascular Effects, Safety and Tolerability in Subjects With Raynaud's Phenomenon Secondary to Systemic Sclerosis Completed NCT02228850 Phase 2 Alprostadil
30 Efficacy and Safety of Vascana® in Subjects With Secondary Raynaud's Phenomenon Completed NCT02688270 Phase 2 Vascana (0.9% nitroglycerin cream);Vehicle (placebo)
31 Digital Flow Enhancement in Raynaud's Phenomenon With an sGC (Soluble Guanylate Cyclase) Stimulator Completed NCT01926847 Phase 2 Riociguat (Adempas, BAY63-2521);Placebo
32 Efficacy and Tolerability of Ginkgo Biloba Extract in Patients With Raynaud´s Phenomenon Completed NCT00251238 Phase 2 Ginkgo biloba extract EGb 761
33 Dose Response Study of a Topical Formulation of Nitroglycerin for the Treatment of Raynaud's Phenomenon Completed NCT00480753 Phase 2 Nitroglycerin
34 PF-00489791 For The Treatment Of Raynaud's Completed NCT01090492 Phase 2 PF-00489791;PF-00489791;PF-00489791;PF-00489791;PF-00489791;PF-00489791;PF-00489791;PF-00489791
35 Dose Response Study of a Topical Gel for the Treatment of Raynaud's Phenomenon Completed NCT00378521 Phase 2 MQX-503
36 Trial of IC351 in Female Scleroderma Patients With Raynaud's and Sexual Dysfunction Completed NCT00707187 Phase 2 Cialis
37 A Two-Part Study of BOTOX® Therapy for Ischemic Digits Completed NCT01309802 Phase 2 onabotulinum toxin type-A
38 Digital Ischemic Lesions in Scleroderma Treated With Oral Treprostinil Diethanolamine Completed NCT00775463 Phase 2 treprostinil diethanolamine;placebo
39 Phase II Study of Recombinant Relaxin for Progressive Systemic Sclerosis Completed NCT00004380 Phase 2 relaxin
40 Imatinib in Systemic Sclerosis Completed NCT00506831 Phase 1, Phase 2 Imatinib mesylate
41 Riociguat in Scleroderma Associated Digital Ulcers Completed NCT02915835 Phase 2 Riociguat;Placebo
42 Evaluate Safety & Immunogenicity of a Pandemic Influenza Vaccine (GSK1562902A) in Children Completed NCT00502593 Phase 2
43 Atorvastatin for Microvascular Endothelial Function and Raynaud in Early Diffuse Scleroderma Recruiting NCT02370784 Phase 2 atorvastatin;Placebo
44 Brentuximab Vedotin for Systemic Sclerosis Recruiting NCT03222492 Phase 1, Phase 2
45 Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH) Active, not recruiting NCT01086540 Phase 2
46 Early Treatment of Borderline Pulmonary Arterial Hypertension Associated With Systemic Sclerosis (SSc-APAH) Active, not recruiting NCT02290613 Phase 2 Ambrisentan;Placebo
47 SCLERoderma et Adipose-DErived Stroma Cells Not yet recruiting NCT02866552 Phase 2 Stromal Vascular fraction;Ringer lactate
48 Efficacy of ORM-12741 for Prevention of Raynaud's Phenomenon Terminated NCT01315899 Phase 2 ORM-12471 30mg;ORM-12471;placebo
49 Effect of Different Iloprost Doses on Symptoms in Systemic Sclerosis Terminated NCT00622687 Phase 2 iloprost;iloprost low dose;iloprost therapy up to 2 ng/kg x min
50 Open-Label Study of Oral Treprostinil in Digital Ulcers Terminated NCT00848107 Phase 2 treprostinil diethanolamine

Search NIH Clinical Center for Raynaud Phenomenon

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Genetic Tests for Raynaud Phenomenon

Anatomical Context for Raynaud Phenomenon

MalaCards organs/tissues related to Raynaud Phenomenon:

41
Heart, Skin, Endothelial, Lung, Bone, Thyroid, Bone Marrow

Publications for Raynaud Phenomenon

Articles related to Raynaud Phenomenon:

(show top 50) (show all 154)
# Title Authors Year
1
Ischaemic ulcers on the toes secondary to Raynaud phenomenon in a patient with systemic sclerosis successfully treated with botulinum toxin. ( 29274125 )
2018
2
Impairment of microcirculation and vascular responsiveness in adolescents with primary Raynaud phenomenon. ( 29566759 )
2018
3
The Frisbee maneuver: A novel method to abort acute attacks of the Raynaud phenomenon. ( 29017842 )
2018
4
Nifedipine cream versus sildenafil cream for patients with secondary Raynaud phenomenon: A randomized, double-blind, controlled pilot study. ( 29241781 )
2018
5
Antiphosphatidylserine/prothrombin (aPS/PT) antibodies are associated with Raynaud phenomenon and migraine in primary thrombotic antiphospholipid syndrome. ( 29338587 )
2018
6
Effect of topical rosemary essential oil on Raynaud phenomenon in systemic sclerosis. ( 30219447 )
2018
7
Botulinum Toxin Injection for Lower Face and Oral Cavity Raynaud Phenomenon After Mandibulectomy, Free Fibula Reconstruction, and Radiation Therapy. ( 30260839 )
2018
8
On-Demand Sildenafil as a Treatment for Raynaud Phenomenon: A Series of n-of-1 Trials. ( 30383134 )
2018
9
Treating Raynaud phenomenon: Beyond staying warm. ( 28985172 )
2017
10
Follow-Up of Treatment Response With Dynamic Doppler Ultrasound in Raynaud Phenomenon. ( 28981361 )
2017
11
Popliteal artery entrapment syndrome presenting as Raynaud phenomenon. ( 28633610 )
2017
12
Finger pad tophi in a patient with Raynaud phenomenon. ( 28180145 )
2017
13
Unexpected drug-induced Raynaud phenomenon: Analysis from the French national pharmacovigilance database. ( 28336160 )
2017
14
Response to Letter Regarding Article, "Relation of Nailfold Capillaries and Autoantibodies to Mortality in Patients With Raynaud Phenomenon". ( 27245655 )
2016
15
Relation of Nailfold Capillaries and Autoantibodies to Mortality in Patients With Raynaud Phenomenon. ( 26733605 )
2016
16
Raynaud phenomenon causing lingual pallor and dysarthria. ( 27114484 )
2016
17
Iatrogenic Thenar Eminence Atrophy After Botox A Injection for Secondary Raynaud Phenomenon. ( 27660946 )
2016
18
Letter by Boulon and Constans Regarding Article, "Relation of Nailfold Capillaries and Autoantibodies to Mortality in Patients With Raynaud Phenomenon". ( 27245654 )
2016
19
Aberrant immune response with consequent vascular and connective tissue remodeling - causal to scleroderma and associated syndromes such as Raynaud phenomenon and other fibrosing syndromes? ( 27548652 )
2016
20
Nailfold Capillary Patterns in a Patient With Multicentric Reticulohistiocytosis and Raynaud Phenomenon. ( 27219314 )
2016
21
Raynaud Phenomenon With Severe Ulcers Associated With Cryoglobulins in an HIV+ but HCV Negative Patient. ( 27433994 )
2016
22
A case report of the beneficial effects of botulinum toxin type A on Raynaud phenomenon in a patient with lung cancer. ( 27749585 )
2016
23
Abnormal Bone Marrow Signal Intensity in the Phalanges of the Foot as a Manifestation of Raynaud Phenomenon: A Report of Six Patients. ( 27575610 )
2016
24
Neonatal BehAset's disease with Raynaud phenomenon. ( 27834783 )
2016
25
The cardiac magnetic resonance in the diagnosis of cardiac Raynaud phenomenon in a patient with systemic sclerosis: case report and review of literature. ( 26692357 )
2016
26
The Role of Botulinum Toxin A in the Treatment of Raynaud Phenomenon. ( 26808752 )
2016
27
Thermal Disparity between Fingers after Cold-water Immersion of Hands: A Useful Indicator of Disturbed Peripheral Circulation in Raynaud Phenomenon Patients. ( 26935364 )
2016
28
Primary sclerosing cholangitis associated with CREST (calcinosis, Raynaud phenomenon, oesophageal dysmotility, sclerodactyly and telangiectasia) in an elderly woman: a case report. ( 26607041 )
2015
29
Prevalence of Raynaud phenomenon and nailfold capillaroscopic abnormalities in Fabry disease: a cross-sectional study. ( 25997047 )
2015
30
A vascular mechanistic approach to understanding Raynaud phenomenon. ( 25536485 )
2015
31
Fat grafting to the hand in patients with raynaud phenomenon: a novel therapeutic modality. ( 25539337 )
2015
32
Reply: fat grafting to the hand in patients with raynaud phenomenon: a novel therapeutic modality. ( 25539338 )
2015
33
Therapeutic hypothermia after cardiac arrest in a patient with systemic sclerosis and Raynaud phenomenon. ( 25644911 )
2015
34
Raynaud phenomenon and mortality: 20+ years of follow-up of the Charleston Heart Study cohort. ( 25678814 )
2015
35
How can follow-up of patients with Raynaud phenomenon be optimized? ( 25847811 )
2015
36
Nasal septal perforation reconstruction with superior-based pedicled nasolabial island flap in a patient with the Raynaud phenomenon. ( 25974818 )
2015
37
Use of Laser Speckle Contrast Imaging to Assess Digital Microvascular Function in Primary Raynaud Phenomenon and Systemic Sclerosis: A Comparison Using the Raynaud Condition Score Diary. ( 26034146 )
2015
38
Understanding Raynaud phenomenon. ( 26083293 )
2015
39
Lingual Raynaud phenomenon. ( 26195579 )
2015
40
Management of Raynaud Phenomenon and Digital Ulcers in Scleroderma. ( 26210127 )
2015
41
Recognizing and treating Raynaud phenomenon. ( 26501577 )
2015
42
Raynaud Phenomenon. ( 26650667 )
2015
43
Minimally invasive treatment of Raynaud phenomenon: the role of botulinum type A. ( 24286738 )
2014
44
Fat grafting to the hand in patients with Raynaud phenomenon: a novel therapeutic modality. ( 24445877 )
2014
45
Getting in touch with Raynaud phenomenon. ( 24646581 )
2014
46
Successfully treated fingertip necrosis in an infant with primary Raynaud phenomenon. ( 24796412 )
2014
47
Laser speckle contrast imaging of Raynaud phenomenon. ( 25042024 )
2014
48
Effectiveness of calcium channel blockers for Raynaud phenomenon. ( 25077719 )
2014
49
Interferons beta have vasoconstrictive and procoagulant effects: A woman who developed livedo reticularis and Raynaud phenomenon in association with interferon beta treatment for multiple sclerosis. ( 24321162 )
2013
50
Prevalence of migraine and Raynaud phenomenon in women with apical ballooning syndrome (Takotsubo or stress cardiomyopathy). ( 23415512 )
2013

Variations for Raynaud Phenomenon

Expression for Raynaud Phenomenon

Search GEO for disease gene expression data for Raynaud Phenomenon.

Pathways for Raynaud Phenomenon

Pathways related to Raynaud Phenomenon according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.43 ADRA2C APOH PDE5A THBD VWF
2
Show member pathways
11.97 ADRA2C AGTR1 PDE5A
3 10.79 AGTR1 EDN1 THBD

GO Terms for Raynaud Phenomenon

Cellular components related to Raynaud Phenomenon according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of postsynaptic membrane GO:0099055 8.96 ADRA2C HTR2A
2 Weibel-Palade body GO:0033093 8.62 EDN1 VWF

Biological processes related to Raynaud Phenomenon according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor signaling pathway GO:0007186 9.87 ADRA2C AGTR1 EDN1 HTR2A
2 positive regulation of cytosolic calcium ion concentration GO:0007204 9.61 AGTR1 EDN1 HTR2A
3 phospholipase C-activating G protein-coupled receptor signaling pathway GO:0007200 9.56 AGTR1 HTR2A
4 sensory perception of pain GO:0019233 9.55 EDN1 HTR2A
5 hemostasis GO:0007599 9.54 THBD VWF
6 phosphatidylinositol 3-kinase signaling GO:0014065 9.52 EDN1 HTR2A
7 regulation of sensory perception of pain GO:0051930 9.51 ADRA2C EDN1
8 positive regulation of cytosolic calcium ion concentration involved in phospholipase C-activating G protein-coupled signaling pathway GO:0051482 9.49 AGTR1 EDN1
9 positive regulation of vasoconstriction GO:0045907 9.48 ADRA2C HTR2A
10 positive regulation of cardiac muscle hypertrophy GO:0010613 9.46 EDN1 PDE5A
11 blood coagulation, intrinsic pathway GO:0007597 9.4 APOH VWF
12 artery smooth muscle contraction GO:0014824 9.37 EDN1 HTR2A
13 positive regulation of MAP kinase activity GO:0043406 9.33 EDN1 HTR2A PDE5A
14 negative regulation of fibrinolysis GO:0051918 9.32 APOH THBD
15 negative regulation of smooth muscle cell apoptotic process GO:0034392 9.26 APOH EDN1
16 regulation of vasoconstriction GO:0019229 9.13 ADRA2C AGTR1 EDN1
17 negative regulation of blood coagulation GO:0030195 8.8 APOH EDN1 THBD

Sources for Raynaud Phenomenon

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....